J-STAGE Home  >  Publications - Top  > Bibliographic Information

Journal of Atherosclerosis and Thrombosis
Vol. 13 (2006) No. 2 P 82-89

Language:

http://doi.org/10.5551/jat.13.82

Original Article

To date, the glycoprotein endoglin and its receptor complex, formed between TGFβ and TGFβ R-2, have been studied in tumor angiogenesis. The purpose of this study is to investigate the expression profile of endoglin and its receptor complex in human atherosclerotic lesions, and compare it to that in non-atherosclerotic tissues. Twenty-six atherosclerotic lesions and twenty-six non-atherosclerotic aortic tissues were collected from thirty-six autopsy cases. Indirect immunohistochemical staining was performed to detect the presence of endoglin, TGFβ-1, and TGFβ R-2 proteins in aortic tissues. Endoglin expression was observed in smooth muscle cells (SMC), macrophages and endothelial cells of aortic atherosclerotic lesions. The levels of TGFβ-1 and TGFβ R-2 were increased in the intimal matrices, smooth muscle cells, and macrophages, as well as in endothelial cells. The expression levels of endoglin, TGFβ-1, and TGFβ R-2 were higher in atherosclerotic lesions than in non-atherosclerotic aortic tissues (p < 0.0001), and there was a correlation among the expression of endoglin, TGFβ-1, and TGFβ R-2 in atherosclerotic aortic lesions (p < 0.001). Endoglin or its receptor complex may participate in the atherogenesis.

Article Tools

Share this Article